DrugId:  1
1. Name:  Aviptadil
2. Groups:  Approved
3. Description:  Not Available
4. Indication:  Not Available
DrugId:  2
1. Name:  Virginiamycin S1
2. Groups:  Experimental
3. Description:  One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae, s. Loidensis, s. Mitakaensis, s. Pristina-spiralis, s. Ostreogriseus, and others. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.
4. Indication:  Not Available
DrugId:  3
1. Name:  Neratinib
2. Groups:  Approved, Investigational
3. Description:  Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
4. Indication:  For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy [FDA Label].
